Every 10-Q that Penumbra Inc (PEN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PEN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PEN filings page.
Penumbra, Inc. reported Q2 2026 revenue of $390.0 million, up 14.9% year over year, driven by thrombectomy and embolization products, particularly in the United States. Gross margin improved to 67.9%, but net income declined to $34.8 million (diluted EPS $0.88) from $45.3 million, mainly due to higher SG&A, including acquisition-related expenses, and a higher effective tax rate.
The company has entered into a definitive agreement to be acquired by Boston Scientific Corporation for $374 per share, implying an enterprise value of approximately $14.5 billion, with consideration paid about 73% in cash and 27% in Boston Scientific stock. Penumbra ended June 30, 2026 with $205.3 million in cash and equivalents, $453.5 million in marketable investments, and generated $133.1 million of operating cash flow in the first half of 2026, supporting manufacturing expansion and R&D.
Penumbra, Inc. reported first‑quarter 2026 revenue of $374.8 million, up 15.6% from $324.1 million a year earlier, driven by growth in both thrombectomy and embolization/access products. Thrombectomy revenue reached $253.9 million, while embolization and access products generated $120.8 million.
Gross margin improved to 67.6% from 66.6%, but higher operating expenses, including acquisition‑related costs, reduced net income to $32.6 million from $39.2 million, with diluted EPS declining to $0.82 from $1.00. Operating cash flow strengthened to $87.0 million, supporting cash and cash equivalents of $241.3 million and marketable investments of $374.4 million.
The company entered into a definitive agreement to be acquired by Boston Scientific at $374 per Penumbra share, valuing the transaction at approximately $14.5 billion, with consideration mix targeted at roughly 73% cash and 27% Boston Scientific stock, subject to shareholder and regulatory approvals.
Penumbra (PEN) reported stronger Q3 results with revenue of $354.7 million, up from $301.0 million a year ago, and net income of $45.9 million versus $29.5 million. Operating income rose to $48.8 million from $35.4 million as gross profit increased to $240.4 million. Thrombectomy contributed $236.4 million and Embolization & Access $118.3 million. U.S. sales were $275.0 million and international $79.7 million.
For the first nine months, revenue reached $1,018.3 million (from $879.1 million) and net income was $130.3 million compared to a loss of $19.7 million last year. Cash and cash equivalents were $321.0 million, with $149.3 million in marketable investments, and operating cash flow of $152.2 million year‑to‑date. The company is building a ~330,000 sq. ft. Costa Rica facility, expecting about $35 million in project costs plus $23 million of improvements; $28.3 million was paid through Q3. The board extended the remaining $100.0 million share repurchase authorization to December 31, 2025. The prior immersive healthcare wind‑down carried no new charges in 2025.